Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia.
Katherine Ismei ZhouChenyu LinJadee Lee NeffAhmed GalalPublished in: BMJ case reports (2023)
The tyrosine kinase inhibitor dasatinib is approved for the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL). Patients on dasatinib can rarely develop a form of benign reversible reactive lymphadenopathy termed follicular lymphoid hyperplasia (FLH). Here, we describe a patient with Ph+ ALL who developed follicular lymphoma (FL) after prolonged treatment with dasatinib and who had complete remission of FL after discontinuation of dasatinib. This case suggests that dasatinib-associated FLH could be a premalignant condition that can transform into FL. Moreover, withdrawal of dasatinib may be sufficient for remission of dasatinib-associated FL.
Keyphrases
- chronic myeloid leukemia
- liver failure
- end stage renal disease
- case report
- chronic kidney disease
- respiratory failure
- newly diagnosed
- acute lymphoblastic leukemia
- ejection fraction
- disease activity
- rheumatoid arthritis
- prognostic factors
- immune response
- genome wide
- gene expression
- peritoneal dialysis
- intensive care unit
- ulcerative colitis
- combination therapy